1884220-36-3 Usage
Description
SBI-0206965 is a potent and selective inhibitor of ULK1, a serine/threonine kinase that plays a crucial role in the regulation of autophagy. It has an IC50 of 108 nM against ULK1 and is less effective against ULK2 (IC50 = 711 nM). SBI-0206965 is highly selective for ULK1 and ULK2, showing minimal activity against a panel of 456 additional kinases. SBI-0206965 suppresses autophagy induced by mTOR inhibition and blocks ULK1-dependent cell survival following nutrient deprivation.
Uses
Used in Pharmaceutical Industry:
SBI-0206965 is used as a research tool for studying the role of ULK1 in autophagy and cell survival. Its ability to inhibit ULK1 makes it a valuable compound for investigating the mechanisms underlying nutrient deprivation and autophagy regulation.
Used in Cancer Research:
SBI-0206965 is used as a potential therapeutic agent for targeting cancer cells that rely on autophagy for survival. By inhibiting ULK1, the compound can disrupt the autophagy process, leading to the suppression of tumor growth and the enhancement of the effectiveness of other cancer treatments.
Used in Neurodegenerative Disease Research:
SBI-0206965 is used as a research compound to explore the role of autophagy in neurodegenerative diseases, such as Alzheimer's, Parkinson's, and Huntington's disease. The modulation of autophagy through the inhibition of ULK1 may provide insights into the development of novel therapeutic strategies for these conditions.
Used in Drug Discovery:
SBI-0206965 serves as a starting point for the development of new drugs targeting the ULK1 pathway. Its selectivity and potency make it an attractive candidate for further optimization and the design of more effective and specific inhibitors for various therapeutic applications.
Biochem/physiol Actions
Since most of the tumor cells survive on autophagy mechanism, inhibition of autophagy inducers Unc-51 (serine/threonine-protein kinase)-like autophagy activating kinase (ULK1 and ULK2) might be useful in cancer therapy.
References
1) Egan?et al. (2015), Small Molecules Inhibition of the Autophagy Kinase ULK1 and Identification of ULK1 Substrates; Mol. Cell, 59?285
Check Digit Verification of cas no
The CAS Registry Mumber 1884220-36-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,8,4,2,2 and 0 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1884220-36:
(9*1)+(8*8)+(7*8)+(6*4)+(5*2)+(4*2)+(3*0)+(2*3)+(1*6)=183
183 % 10 = 3
So 1884220-36-3 is a valid CAS Registry Number.
1884220-36-3Relevant articles and documents
NOVEL ULK1 INHIBITORS AND METHODS USING SAME
-
Page/Page column 176; 175, (2016/03/22)
In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.
